LakeShore Biopharma Co Accounts Payable

As of the most recent data (March 2025), LSB shows a accounts payable of $50M. That compares with $68M in the prior-year period — down 26.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, LSB's accounts payable is now $50M (was $68M) — a 26.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether LakeShore Biopharma Co is outperforming or lagging.

Tracking LSB's accounts payable over time shows whether LakeShore Biopharma Co is scaling, shrinking, or reshaping that part of the business. The current reading is $50M That compares with $68M in the prior-year period — down 26.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has LakeShore Biopharma Co's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $50M) with ownership activity and broader fundamentals.